BERHANE MEBRATU: Open Payments
NPI 1043718927 · PORTLAND, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,975 in 107 payments from 44 companies in 2025. Trend: 2023 $1,997 · 2024 $2,980 · 2025 $2,975
Food & beverage: $2,796Education: $178
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 11 | $274 |
| Astellas Pharma US Inc | 3 | $201 |
| Merck Sharp & Dohme LLC | 8 | $201 |
| PFIZER INC. | 8 | $169 |
| AstraZeneca Pharmaceuticals LP | 6 | $160 |
| ABBVIE INC. | 6 | $143 |
| Janssen Biotech, Inc. | 5 | $140 |
| Genentech USA, Inc. | 4 | $121 |
| E.R. Squibb & Sons, L.L.C. | 4 | $112 |
| Celgene Corporation | 3 | $109 |
Products named: KEYTRUDA, VENCLEXTA, SCEMBLIX, REBLOZYL, LYNPARZA, OJJAARA, Enhertu, TAVALISSE.
Industry payments across OR — which companies pay providers there.
